AVEO Pharmaceuticals to Present at IBC’s New Frontiers in Cancer Drug Development Conference
CAMBRIDGE, Mass., July 30, 2009 – AVEO Pharmaceuticals, Inc. today announced that Murray Robinson, Ph.D., senior vice president, oncology, is scheduled to present at IBC’s New Frontiers in Cancer Drug Development Conference on Tuesday, August 4, 2009 at 1:40 p.m. (EDT) at the World Trade Center Boston/Seaport Hotel in Boston, Mass.
Dr. Robinson will give a presentation titled “VEGF Pathway Response Biomarkers Using Population-based Preclinical Models” in a pre-conference workshop. This presentation will explore AVEO’s unique translational biology platform that queries entire populations of genetically engineered tumor models for drug response.
AVEO is a late-stage biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics. AVEO’s proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets and therapies. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR, ErbB3 and NOTCH), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals, Schering-Plough and Biogen Idec. The company’s lead product, tivozanib (AV-951), a triple VEGF receptor inhibitor, recently completed Phase 2 clinical development in patients with metastatic renal cell cancer and is expected to enter Phase 3 development in 2009. Through a combination of internal drug discovery and selective in-licensing of targeted therapeutics, AVEO is building a diversified product pipeline and moving toward its vision of becoming a fully integrated biopharmaceutical company. For more information, please visit the company's website at www.aveopharma.com.